Trader consensus reflects an 82.5% implied probability for no new COVID variant of concern before 2027, anchored by the WHO's stringent criteria unmet by recent strains amid SARS-CoV-2's endemic stability. The BA.3.2 ("Cicada") subvariant, which surged in 30+ U.S. states and Europe through April 2026, drew monitoring for immune escape mutations but showed no increased severity, hospitalizations, or diagnostic failures—keeping it as a variant under monitoring rather than concern. Low test positivity below 2%, broad vaccine efficacy against circulating lineages like JN.1 descendants, and routine genomic surveillance signal controlled evolution. Without fresh surges or public health disruptions, traders anticipate no VOC escalation by year's end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoSì
$238,498 Vol.
$238,498 Vol.
Sì
$238,498 Vol.
$238,498 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Mercato aperto: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus reflects an 82.5% implied probability for no new COVID variant of concern before 2027, anchored by the WHO's stringent criteria unmet by recent strains amid SARS-CoV-2's endemic stability. The BA.3.2 ("Cicada") subvariant, which surged in 30+ U.S. states and Europe through April 2026, drew monitoring for immune escape mutations but showed no increased severity, hospitalizations, or diagnostic failures—keeping it as a variant under monitoring rather than concern. Low test positivity below 2%, broad vaccine efficacy against circulating lineages like JN.1 descendants, and routine genomic surveillance signal controlled evolution. Without fresh surges or public health disruptions, traders anticipate no VOC escalation by year's end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti